Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.

Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM.

JAMA Intern Med. 2014 Jul;174(7):1126-34. doi: 10.1001/jamainternmed.2014.1232.

2.

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group..

JAMA. 2006 Dec 27;296(24):2927-38.

PMID:
17190893
3.

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group..

J Bone Miner Res. 2004 Aug;19(8):1259-69. Epub 2004 Mar 29.

4.

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.

Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM; Fracture Intervention Research Group..

J Bone Miner Res. 2006 Feb;21(2):292-9. Epub 2005 Oct 31.

5.

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.

Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD; Fracture Intervention Trial Study Group..

J Bone Miner Res. 2004 Aug;19(8):1250-8. Epub 2004 May 24.

6.
7.

BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate.

McNabb BL, Vittinghoff E, Schwartz AV, Eastell R, Bauer DC, Ensrud K, Rosenberg E, Santora A, Barrett-Connor E, Black DM.

J Bone Miner Res. 2013 Jun;28(6):1319-27. doi: 10.1002/jbmr.1864.

8.

Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Iwamoto J, Uzawa M.

Clin Rheumatol. 2016 Jan;35(1):205-12. doi: 10.1007/s10067-014-2812-y. Epub 2014 Nov 1.

PMID:
25367347
9.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
10.
11.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

12.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ.

JAMA. 1998 Dec 23-30;280(24):2077-82.

PMID:
9875874
13.

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.

Finkelstein JS, Wyland JJ, Lee H, Neer RM.

J Clin Endocrinol Metab. 2010 Apr;95(4):1838-45. doi: 10.1210/jc.2009-1703. Epub 2010 Feb 17.

14.

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.

Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM; FLEX Research Group..

J Bone Miner Res. 2010 May;25(5):976-82. doi: 10.1002/jbmr.11.

15.

Prevention of bone loss after withdrawal of tamoxifen.

Cohen A, Fleischer JB, Johnson MK, Brown IN, Joe AK, Hershman DL, McMahon DJ, Silverberg SJ.

Endocr Pract. 2008 Mar;14(2):162-7.

16.

Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.

Frost ML, Siddique M, Blake GM, Moore AE, Marsden PK, Schleyer PJ, Eastell R, Fogelman I.

Osteoporos Int. 2012 Aug;23(8):2107-16. doi: 10.1007/s00198-011-1805-9. Epub 2011 Oct 8.

PMID:
21983795
17.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
18.

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd.

Am J Med. 1997 Oct;103(4):291-7.

PMID:
9382121
19.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.

PMID:
9531231
20.

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.

Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.

J Clin Endocrinol Metab. 2013 Dec;98(12):4727-35. doi: 10.1210/jc.2013-2020. Epub 2013 Sep 24.

PMID:
24064689

Supplemental Content

Support Center